214 related articles for article (PubMed ID: 29558289)
1. Therapeutic potential of glycyrrhetinic acids: a patent review (2010-2017).
Hussain H; Green IR; Shamraiz U; Saleem M; Badshah A; Abbas G; Rehman NU; Irshad M
Expert Opin Ther Pat; 2018 May; 28(5):383-398. PubMed ID: 29558289
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents.
Hussain H; Ali I; Wang D; Hakkim FL; Westermann B; Ahmed I; Ashour AM; Khan A; Hussain A; Green IR; Shah STA
Expert Opin Drug Discov; 2021 Dec; 16(12):1497-1516. PubMed ID: 34294017
[TBL] [Abstract][Full Text] [Related]
3. Ursolic acid derivatives for pharmaceutical use: a patent review (2012-2016).
Hussain H; Green IR; Ali I; Khan IA; Ali Z; Al-Sadi AM; Ahmed I
Expert Opin Ther Pat; 2017 Sep; 27(9):1061-1072. PubMed ID: 28637397
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel heterocyclic ring-fused 18β-glycyrrhetinic acid derivatives with antitumor and antimetastatic activity.
Gao C; Dai FJ; Cui HW; Peng SH; He Y; Wang X; Yi ZF; Qiu WW
Chem Biol Drug Des; 2014 Aug; 84(2):223-33. PubMed ID: 24612785
[TBL] [Abstract][Full Text] [Related]
5. First Occurrence of a Furano-glycyrrhetinoate and Its Cytotoxicity.
Heller L; Sommerwerk S; Tzschöckell F; Wiemann J; Schwarz S; Siewert B; Al-Harrasi A; Csuk R
Arch Pharm (Weinheim); 2015 Dec; 348(12):889-96. PubMed ID: 26548762
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of triazole linked glycosylated 18β-glycyrrhetinic acid derivatives as anticancer agents.
Parida PK; Sau A; Ghosh T; Jana K; Biswas K; Raha S; Misra AK
Bioorg Med Chem Lett; 2014 Aug; 24(16):3865-8. PubMed ID: 25027936
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship.
Roohbakhsh A; Iranshahy M; Iranshahi M
Curr Med Chem; 2016; 23(5):498-517. PubMed ID: 26758798
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pro-apoptotic activity of novel glycyrrhetinic acid derivatives.
Logashenko EB; Salomatina OV; Markov AV; Korchagina DV; Salakhutdinov NF; Tolstikov GA; Vlassov VV; Zenkova MA
Chembiochem; 2011 Mar; 12(5):784-94. PubMed ID: 21328513
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of boswellic acids: a patent review (1990-2015).
Hussain H; Al-Harrasi A; Csuk R; Shamraiz U; Green IR; Ahmed I; Khan IA; Ali Z
Expert Opin Ther Pat; 2017 Jan; 27(1):81-90. PubMed ID: 27646163
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of ring A modified glycyrrhetinic acid derivatives.
Csuk R; Schwarz S; Siewert B; Kluge R; Ströhl D
Eur J Med Chem; 2011 Nov; 46(11):5356-69. PubMed ID: 21959232
[TBL] [Abstract][Full Text] [Related]
11. Does one keto group matter? Structure-activity relationships of glycyrrhetinic acid derivatives modified at position C-11.
Csuk R; Schwarz S; Kluge R; Ströhl D
Arch Pharm (Weinheim); 2012 Jan; 345(1):28-32. PubMed ID: 22076975
[TBL] [Abstract][Full Text] [Related]
12. Modification, Antitumor Activity, and Targeted PPARγ Study of 18β-Glycyrrhetinic Acid, an Important Active Ingredient of Licorice.
Sun J; Liu HY; Lv CZ; Qin J; Wu YF
J Agric Food Chem; 2019 Aug; 67(34):9643-9651. PubMed ID: 31390199
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Anticancer Activities of Glycyrrhetinic Acid Derivatives.
Li Y; Feng L; Song ZF; Li HB; Huai QY
Molecules; 2016 Feb; 21(2):. PubMed ID: 26861280
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the cytotoxicity and tumor selectivity of glycyrrhetinic acid by derivatization with bifunctional amino acids.
Csuk R; Schwarz S; Kluge R; Ströhl D
Arch Pharm (Weinheim); 2011 Aug; 344(8):505-13. PubMed ID: 21674592
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor agents 255: novel glycyrrhetinic acid-dehydrozingerone conjugates as cytotoxic agents.
Tatsuzaki J; Taniguchi M; Bastow KF; Nakagawa-Goto K; Morris-Natschke SL; Itokawa H; Baba K; Lee KH
Bioorg Med Chem; 2007 Sep; 15(18):6193-9. PubMed ID: 17591444
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
18. An Overview of Structurally Modified Glycyrrhetinic Acid Derivatives as Antitumor Agents.
Xu B; Wu GR; Zhang XY; Yan MM; Zhao R; Xue NN; Fang K; Wang H; Chen M; Guo WB; Wang PL; Lei HM
Molecules; 2017 Jun; 22(6):. PubMed ID: 28574470
[TBL] [Abstract][Full Text] [Related]
19. Conversions at C-30 of glycyrrhetinic acid and their impact on antitumor activity.
Csuk R; Schwarz S; Siewert B; Kluge R; Ströhl D
Arch Pharm (Weinheim); 2012 Mar; 345(3):223-30. PubMed ID: 21997717
[TBL] [Abstract][Full Text] [Related]
20. Microbial transformation of glycyrrhetinic acid by Mucor polymorphosporus.
Xin X; Liu Y; Ye M; Guo H; Guo D
Planta Med; 2006 Feb; 72(2):156-61. PubMed ID: 16491452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
